AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
This brief overview contrasts lifecycle funds with target date funds, highlighting key distinctions to help you choose the right fund for retirement planning.
18,693 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
A new VA loan fee package moves through Congress, raising costs for refinances and assumptions. Industry groups warn ...
El Salvador continues to pursue a plan to buy one Bitcoin per day, even as an IMF loan program restricts public-secto...
Private SpaceX uses extended lockups for insiders, signaling a disciplined cash strategy. This article breaks down wh...
President Trump’s Mount Rushmore appearance on Independence Day stirred political headlines and market caution. Early...
As 2026 unfolds, investors face a clear choice between Lilly's growth engine in big markets and Teva's value-forward ...
On a volatile trading day, fuelcell energy stock tumbling becomes a talking point for traders and long-term holders a...
Two semiconductor giants vie for AI-led growth. This article breaks down how revenue growth rates and company scale s...
Rising costs and higher rates are pressuring traditional bonds. More retirees replacing bond allocations with dividen...
Jim Cramer's ongoing Nvidia purchases rest on one core belief: the CUDA software moat that underpins Nvidia's AI lead...
July brings a tech-driven reshuffle in enterprise budgets. IBM warned of softer Q2 demand as clients pivot toward AI ...
Fidelis Investors closed its fourth rated residential transition loan securitization, a $191.5 million deal backed by...